# MLC1501 Study Assessing Efficacy in Post STrOke Subjects With mOtor Deficits

Study · id `cardio:ct-nct05289947` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05289947](<https://clinicaltrials.gov/study/NCT05289947>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05289947

Browse, organ or system: Heart; Brain  
Browse, condition area: Coronary and vascular disease; Stroke; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 303 participants.

## Technical summary

Registry record NCT05289947. Randomized; quadruple masking; primary purpose treatment. Start 2023-07-21 (actual); primary completion 2025-07-18 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 303 participants (enrolled count; ClinicalTrials.gov record NCT05289947, source copy `cardio:ctgov-nct05289947-2025-12-09`, retrieved 2026-10-26)
- Started: 2023-07-21 (actual) (ClinicalTrials.gov record NCT05289947, source copy `cardio:ctgov-nct05289947-2025-12-09`, retrieved 2026-10-26)
- Primary completion: 2025-07-18 (actual) (ClinicalTrials.gov record NCT05289947, source copy `cardio:ctgov-nct05289947-2025-12-09`, retrieved 2026-10-26)
- Completion: 2025-07-18 (actual) (ClinicalTrials.gov record NCT05289947, source copy `cardio:ctgov-nct05289947-2025-12-09`, retrieved 2026-10-26)
- Countries: Philippines; Singapore (ClinicalTrials.gov record NCT05289947, source copy `cardio:ctgov-nct05289947-2025-12-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05289947-2025-12-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: MLC1501 Study Assessing Efficacy in Post STrOke Subjects With mOtor Deficits
- Acronym: MAESTOSO
- Condition: Stroke
- Condition: Stroke, Ischemic
- Condition: Strokes Thrombotic
- Condition: Stroke Sequelae
- Condition: Stroke, Cardiovascular
- Condition: Stroke, Embolic
- Condition: Stroke, Cryptogenic
- Intervention (Other): Placebo
- Intervention (Drug): MLC1501
- Lead sponsor: Moleac Pte Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Stroke (`core:stroke`)

## Provenance

Content hash: ce86c54ecad0bb8d21489ce726e183c9919fedfd7c42f775a673e656a5bae9ea
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
